Researchers have now found that the vaccine against Respiratory Syncytial Virus (RSV) can prevent hospitalization in a significant majority of older adults and immunocompromised individuals.
The latest study published in the Lancet journal analyzed the effectiveness of the RSV vaccine in U.S. adults aged 60 and older using large-scale data from 36,706 patients. The researchers looked at hospital and emergency room visits for RSV-like illnesses between October 2023 and March 2024 across eight U.S. states. They then compared vaccination rates between patients who tested positive for RSV and those who tested negative while adjusting for factors like age, sex, race, underlying health conditions, and location. There were 3,275 vaccinated patients in the study.
